Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
J Urol. 2010 May;183(5):1751-6. doi: 10.1016/j.juro.2010.01.014. Epub 2010 Mar 17.
The impact of prostate cancer radiotherapy on the biological behavior of bladder cancer remains unclear. We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities.
We identified 144 patients diagnosed with bladder cancer between January 1992 and June 2007 with a previous prostate cancer diagnosis. Clinicopathological data and outcomes were compared between patients with irradiated (brachytherapy and/or external beam radiation therapy 83) and nonirradiated (androgen deprivation therapy, radical prostatectomy and/or surveillance 61) disease.
Median time between prostate and bladder cancer diagnoses was longer in the irradiated vs nonirradiated group (59 months, IQR 25 to 88, vs 24 months, IQR 2 to 87, p = 0.007). Patients in the irradiated group presented with higher tumor grade (high 92% vs 77%, p = 0.016) and had progression to higher stage disease (muscle invasive 70% vs 43%, p = 0.001) than those in the nonirradiated group. Of the patients undergoing cystectomy those previously treated with radiation had a numerically higher rate of nonorgan confined disease (75% vs 56% for nonirradiated, p = 0.1). Among all patients with bladder cancer 5-year cancer specific survival was 73% (95% CI 59-87) for irradiated vs 83% (95% CI 71-95) for nonirradiated (p = 0.07). Median followup was 53 months (IQR 24 to 75).
More time elapsed between prostate and bladder cancer diagnoses for patients treated with radiation, and these patients also presented with more advanced disease. Future studies are needed to further establish clinical differences in bladder cancer between irradiated and nonirradiated cases, and whether biological differences exist.
前列腺癌放疗对膀胱癌生物学行为的影响尚不清楚。我们比较了既往接受前列腺癌放疗与其他治疗方式治疗的膀胱癌患者的结局。
我们确定了 1992 年 1 月至 2007 年 6 月期间 144 例诊断为膀胱癌且此前患有前列腺癌的患者。比较了接受放疗(近距离放疗和/或外照射放疗 83 例)和未接受放疗(雄激素剥夺治疗、根治性前列腺切除术和/或监测 61 例)患者的临床病理数据和结局。
与未接受放疗的患者相比,接受放疗的患者前列腺癌和膀胱癌诊断之间的中位时间更长(59 个月,IQR25-88,vs24 个月,IQR2-87,p=0.007)。放疗组患者肿瘤分级更高(高级别 92%,vs 低级别 77%,p=0.016),进展为更高分期疾病(肌层浸润性 70%,vs 非肌层浸润性 43%,p=0.001)的比例更高。接受膀胱切除术的患者中,既往接受放疗的患者非局限性疾病的比例更高(75%,vs 未接受放疗的 56%,p=0.1)。在所有膀胱癌患者中,放疗组 5 年癌症特异性生存率为 73%(95%CI59-87),未放疗组为 83%(95%CI71-95)(p=0.07)。中位随访时间为 53 个月(IQR24-75)。
接受放疗的患者前列腺癌和膀胱癌诊断之间的时间间隔更长,这些患者也表现出更晚期的疾病。需要进一步开展研究,以明确放疗与非放疗病例之间膀胱癌的临床差异,以及是否存在生物学差异。